3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
35
Gastrointestinal
31
Genitourinary
20
Gynecologic
16
Head & Neck
13
Dermatologic
10
Breast
9
Lymphoid
4
Other solid neoplasm
3
Endocrine
2
Sarcoma
1
NET
1
CNS
1
Conditions
Brain Neoplasms
640
Glioblastoma
573
Glioma
407
Neuroblastoma
174
Neoplasms
125
Astrocytoma
107
Central Nervous System Neoplasms
105
Medulloblastoma
89
Breast Neoplasms
86
Meningioma
85
Carcinoma, Non-Small-Cell Lung
78
Melanoma
76
Lung Neoplasms
70
Sarcoma
65
Ependymoma
64
Neurofibromatosis 1
62
Recurrence
50
Neoplasm Metastasis
48
Oligodendroglioma
47
Meningeal Carcinomatosis
47
Osteosarcoma
46
Diffuse Intrinsic Pontine Glioma
45
Rhabdomyosarcoma
44
Pheochromocytoma
44
Paraganglioma
42
Rhabdoid Tumor
41
Gliosarcoma
40
Pancreatic Neoplasms
39
Sarcoma, Ewing
38
Colorectal Neoplasms
33
Interventions
pembrolizumab
1
lenvatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
CNS
×
1 year
×
Clear all
NCT03797326
2026-05-04
LEAP-005
Merck Sharp & Dohme LLC
Phase 2
Completed
611 enrolled
27 charts